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Introduction
Crohn’s disease (CD) is a chronic and recurrent immune-mediated 
inflammatory disorder of the gastrointestinal tract.1,2 Typically, pa-
tients suffer from chronic intestinal inflammation that follows a 
relapse-remitting pattern, as well as from a variety of complications 
(Table I) that may or may not involve the gut.3,4 Disease activity can 
be classified by the Crohn’s Disease Activity Index5 (CDAI) (Table II), 
and usually, treatment includes various combinations of corticoste-
roid, anti-inflammatory (aminosalicylates), immune-modulating or 
biological therapy.4 While the exact cause of CD is not known, it is 
thought to result from a complex interplay between intestinal bacte-
ria and an environmental trigger in genetically susceptible individu-
als (Figure 1).6 
The interaction between intestinal bacteria and environmental 
triggers creates an abnormal immune response in genetically 
susceptible individuals. The dysregulated immune response, driven 
by the intestinal microbiome, leads to alterations in mucosal barrier 
function, dietary antigen permeability and microbial clearance.
Numerous gene mutations that are associated with abnormal 
innate immune responses or impaired epithelial barrier function 
have been implicated. Specifically, mutations in the CARD15 
or NOD2 gene on chromosome 16 result in improper bacterial 
product recognition, impairment of the innate immune response to 
commensal bacteria and damage to the intestinal mucosa.7-13 The 
dysregulated immune response, driven by the intestinal microbiome, 
leads to proinflammatory cytokine production, particularly tumour 
necrosis factor-alpha (TNF-α), which directly contributes to both 
disease pathogenesis and malnutrition via alterations in mucosal 
inflammatory activity, epithelial permeability to dietary antigens and 
energy intake (appetite).14,15
Low-fibre, high-fat and high-sugar intakes have been implicated 
as some of the environmental triggers in disease development, 
although the role of a pre-illness diet in the pathogenesis of CD 
remains inconclusive.16-18 However, upon diagnosis, nutrition therapy 
plays an integral role in patient care, regardless of disea se activity. 
Malnutrition
Weight loss, low body mass index (BMI) and nutrient deficiencies 
have been well documented in patients with CD, especially during 
active disease. The degree of malnutrition depends upon the extent, 
severity and duration of the disease.19 There is a higher incidence 
of protein energy malnutrition and specific nutrient deficiencies in 
small bowel, compared to colonic, disease.20
Individual or multiple mechanisms can contribute to malnutrition 
(Table III). However, anorexia, active inflammation and increased 
intestinal loss are reported most often.21-26 Evidence suggests 
that in addition to improving nutrition status, nutritional therapy 
in CD functions to downregulate proinflammatory cytokine 
production, promote epithelial healing, modify gut flora, decrease 
gut permeability and antigenic load and promote an overall anti-
inflammatory effect.25
European guidelines27 recommend that 25-30 kcal (105-126 kJ)/kg 
ideal body weight (IBW)/day is optimal to meet energy requirements 
during active CD, although a recent systematic review28 found that 
higher amounts of enteral nutrition (EN) [≥ 30 kcal (126 kJ)/kg up 
to 45 kcal (189 kJ)/kg IBW/day] may be associated with higher 
remission rates. Nonetheless, clinical judgement, based on recent 
clinical and surgical history, takes precedence in calculating actual 
requirements. Recommended nutrients to correct deficiencies and 
prevent bone loss in the case of active CD29 are listed in Table IV.
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Previously, it was thought that once disease activity subsided, 
fat-free mass content would also improve.30-33 The literature now 
suggests that patients in clinical remission may continue to present 
with changes in body composition, as significant reductions in lean 
body mass,34 muscle mass35 and muscle function36-38 have been 
observed. In addition, when used alone, standard anthropometric 
and laboratory indexes, i.e. BMI or albumin, may not accurately 
represent nutrition status during remission.39
Rocha et al found that according to BMI, only 14% of outpatients 
with CD (n = 50) were malnourished, yet when combined with 
additional anthropometric parameters, 36% (n = 18) had fat mass 
depletion (triceps plus subscapula skinfold thickness), and 62% 
(n = 31) had muscle mass depletion (arm muscle area).40 In a 
multicentre, prospective controlled study, Valentini et al reported 
that despite the fact that 76% of patients with CD (n = 94) are 
well nourished according to subjective global assessment, BMI and 
Table I: Disease description, common symptoms and intestinal and extraintestinal complications of Crohn’s disease4
Disease description Common symptoms Intestinal complications Extraintestinal complications
•	 Affects all layers of the gastrointestinal mucosa
•	 Inflammation is not continuous and may skip lesions
•	 Surgery is not curative
•	 The small bowel and colon are affected primarily, 
but the disease may present anywhere from the 
mouth to the anus
•	 Fistulae and abscesses are common
•	 The presence of confluent deep linear ulcers and 
aphthous ulcers
•	 Fat wrapping and thickening of the intestinal wall 
are often diagnostic features that discriminate 
Crohn’s disease from other conditions
•	 Chronic diarrhoea





















•	 Primary sclerosing 
cholangitis*
•	 Osteoporosis
•	 Nephrolithiasis and gallstones
•	 Venous thromboembolism
•	 Nonalcoholic fatty liver 
disease
•	 Ankylosing spondylitis: Chronic, inflammatory disease of the axial skeleton with variable involvement of the peripheral joints and nonarticular structures. Ankylosing spondylitis is a form of spondyloarthritis, a 
chronic, inflammatory arthritis in which immune mechanisms are thought to play a key role.
•	 Aphthous ulcer (canker sore): Type of ulcer that presents as a painful open sore inside the mouth or upper throat, characterised by a break in the mucous membrane.
•	 Episcleritis: Irritation and inflammation of the episclera, a thin layer of tissue that covers the white part (sclera) of the eye. It occurs without an infection.
•	 Erythema nodosum: Inflammation of the fat cells under the skin (panniculitis), characterised by tender, red nodules that are seen on both shins usually.
•	 Primary sclerosing cholangitis: Chronic liver disease that is caused by progressive inflammation and scarring of the bile ducts of the liver. The underlying cause of the inflammation is believed to be 
autoimmunity.
•	 Pyoderma gangrenosum: Condition that causes tissue to become necrotic, causing deep ulcers that occur on the legs usually.
•	 Uveitis (iritis): Swelling and irritation of the uvea, the middle layer of the eye. The uvea provides most of the blood supply to the retina.
Table II: Crohn’s Disease Activity Index used to classify disease activity
Score Definition
CDAI < 150 Inactive or quiescent disease, i.e. remission.
CDAI 150-220 Mild disease characterised by < 10% weight loss 
and potentially increased C-reactive protein levels 
above the upper limit of normal, with no presentation 
of dehydration, fever, abdominal mass, tenderness or 
obstruction.
CDAI 220-450 Moderate disease characterised by weight loss > 10%, 
the presence of a tender mass (no overt obstruction), 
unsuccessful response to treatment and elevated 
C-reactive protein. 
CDAI > 450 Severe disease characterised by intestinal obstruction, 
abscesses, elevated C-reactive protein and cachexia 
(body mass index < 18 kg/m²) in treated, yet persistently 
symptomatic, patients.
The Crohn’s Disease Activity Index was developed by Best et al5 in 1976 and consists of eight 
factors, each added up after adjustment with a weighting factor. Often used for research purposes, 










IBD: irritable bowel disease
Figure 1: The interaction between intestinal bacteria and environmental 
triggers6-8
Table III: Aetiology of malnutrition in patients with Crohn’s disease21-24
•	 Reduced food intake, anorexia and food aversions
•	 Active inflammation
•	 Reduced nutrient use
•	 Increased intestinal losses
•	 Malabsorption
•	 Increased elimination of nutrients due to oxidative stress
•	 Fistulae
•	 Surgical resections
•	 The side-effects of corticosteroids or other medication
•	 Metabolic abnormalities.
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plasma albumin values, body cell mass (measured by bioelectrical 
impedance analysis) and handgrip strength were significantly 
reduced when compared to controls.41 Metabolic abnormalities might 
have also been present, during either active or inactive disease. 
Alterations in diet-induced thermogenesis, reductions in glucose 
oxidation42,43 and increases in lipid oxidation42-45 and resting energy 
expenditure42,46-49 have been reported, compared to healthy controls. 
However, total energy expenditure was only slightly elevated when 
calculated in relation to fat-free mass.33 While routine assessment 
of these parameters may not be feasible in the clinical setting, it 
is important that the dietetic professional is aware of possible 
underlying metabolic abnormalities, particularly during remission. 
The trend of overweight and obesity in patients with CD, in 
combination with undetected malnutrition, is of recent concern. A 
preliminary study reported reduced hand grip strength and muscle 
stores in the absence of other signs of malnutrition in patients with 
quiescent CD. The majority of patients had normal or above normal 
BMI, of whom 40% were classified as overweight or obese.50,51 In 
an outpatient case-control study, Guerreiro et al reported that 32% 
(n = 78) of outpatients with CD had a BMI > 25 kg/m², compared to 
33.8% of controls, despite a significantly lower fat free mass (p-value 
< 0.05) and lower mean daily intake of macro- and micronutrients 
(p-value < 0.05).52 More than half of the patients with CD in the study 
had muscle mass depletion in the absence of overt malnutrition. In 
fact, the most prevalent form of malnutrition in patients with CD was 
an excess in body weight in conjunction with inadequate dietary 
intake. None of the patients took corticosteroids within three months 
of the study. 
Overweight in patients with CD has been shown to increase the risk 
of relapse to active disease53 and the need for earlier surgical inter-
vention,54 and thus should not be seen as an indicator of health, as 
undernutrition impacts negatively on postoperative complications, 
clinical course and mortality.27,55 Furthermore, adipose tissue pro-
duces bioactive molecules, including TNF-α, a known contributing 
factor in the inflammatory disease process.51
Currently, there is no gold standard in clinical practice for nutrition 
assessment in patients with CD. In general, BMI, unintentional weight 
loss, recent intake and iron studies are used to provide a preliminary 
overview of a patient’s nutrition status.20,39 More comprehensive 
assessment can be achieved using additional anthropometry and 
scoring systems, such as the Subjective Global Assessment56 or 
Nutrition Risk Score,57 although patient muscle mass and function 
are not evaluated in the latter assessments.
Osteoporosis
Osteoporosis occurs in up to 50% of patients with CD.58 Contributing 
risk factors include corticosteroid use, inflammation, age, weight 
loss exceeding 10%, malabsorption, low dietary intake, activity, 
hormones and genetics. BMI < 20  kg/m2 is an independent risk 
factor.59-61
Patients who have taken corticosteroids over the long term should 
be considered to be at risk of acquiring fractures.62 However, not 
using the medication does not eliminate the risk of fractures,63 
as vitamin D malabsorption and elevated circulating cytokines 
may also act upon bone turnover rate.61 Corticosteroids should be 
reduced when possible.59 Calcium and vitamin D supplementation is 
recommended when steroid therapy is prescribed for longer than 12 
weeks.64,65 Very emaciated patients may also benefit from calcium 
and vitamin D supplementation. The provision of supplemental EN 
may also offer further benefit. A total of 1 000-1 500 mg calcium 
(dietary or supplemental) is recommended,66,67 with an additional 
800 IU vitamin D daily.66 Patients with CD often avoid dairy products 
because of perceived intolerance. A dietary evaluation of calcium 
intake is essential. Lifestyle activities, such as regular weight-bearing 
exercise and the avoidance of smoking and excessive alcohol intake, 
should be promoted.
Anaemia
Anaemia of various origins occurs in up to 74% of patients with 
CD.68 Anaemia is commonly caused by iron deficiency or anaemia of 
chronic disease (ACD), which involves alterations in erythropoiesis, 
iron homeostasis and red cell survival.69
Several factors, including malabsorption (duodenal and upper jejunal 
involvement), decreased dietary intake of iron-rich foods because 
of food aversions and inflammation, and chronic intestinal blood 
loss contribute to iron deficiency anaemia (IDA).19,64,68 Studies that 
link disease location and activity with iron absorption are lacking. 
However, no difference was found in ferritin and haemoglobin 
levels between patients with CD and those with ulcerative colitis.70 
This suggests an alternate pathogenic factor besides small bowel 
absorption. Assessment of iron status is complex as inflammation 
increases serum ferritin levels (an acute-phase protein). IDA and 
ACD also often coexist.64 Identifying the underlying cause is an 
important step before starting therapy, and diagnostic guidelines, 
based on the presence and absence of inflammation in anaemia, 
Table IV: Nutrients that are important in active Crohn’s disease29
Nutrient Dose Comments
Iron 60 mg/day Supplemental elemental Fe, 
preferably ferrous sulphate or 
gluconate.
Calcium 1 000-1 500 mg/day Calcium carbonate should be 
given with vitamin D to help 
prevent bone loss.




DHA and EPA 1 g/day To lower the use of 
anti-inflammatories.
Magnesium 300 mg/day 
elemental Mg
Magnesium oxide provides 60% of 
elemental Mg, while magnesium 
chloride/lactate provides 12%, but 
higher bioavailability.
Folic acid 800 mg/day To prevent anaemia.
Vitamin B12 1 mg orally/
intramuscularly
For patients with severe ileal 
disease.
Zinc 8 mg elemental Zn 
twice daily
As zinc carnosine.
DHA: docosahexaenoic acid, EPA: eicosapentaenoic acid
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and that allow individual reference values for iron stores, have been 
developed for clinical practice.71,72 When providing supplemental iron, 
intravenous administration may be indicated as oral administration 
often leads to increased gastrointestinal side-effects, including 
diarrhoea, abdominal pain and nausea and potential worsening of 
inflammation.71,72
Vitamin B6, vitamin B12 and folate deficiency
Deficiencies of vitamin B12 and folate have been reported in up to 
48% and 54% of patients with CD, respectively.36 Both folate and 
vitamin B12 are required to clear homocysteine via the homocysteine-
methionine metabolic pathway,73 and low levels of either nutrient 
lead to hyperhomocysteinaemia, a risk factor for prothrombotic 
states and thromboembolism.74-76
A well-known risk factor for developing vitamin B12 deficiency is 
resection of the terminal ileum or ileal CD.68 Annual monitoring and 
parenteral supplementation are recommended in these patients.77 
However, vitamin B12 deficiency is not always due to intestinal 
resection.78 Furthermore, deficiencies have been shown to occur 
despite additional supplementation.39 Routine monitoring of vitamin 
B12 in all patients with CD may be warranted, especially those who 
are unresponsive to iron therapy or who are found to have macrocytic 
anaemia.68
Sulphasalazine treatment is a known risk factor for folate deficiency, 
although deficiencies also arise because of malabsorption and 
dietary insufficiency issues.78 Subnormal vitamin B6 levels have been 
observed, but are likely to be a result of malabsorption, rather than 
dietary insufficiency.70 Routine monitoring and supplementation of 
these vitamins may be required. 
Vitamin A deficiency
Low levels of circulating retinol-binding protein are associated with 
the acute-phase response,79 and in the presence of zinc deficiency, 
secondary to the impairment of protein metabolism.80 Deficiencies 
of vitamin A compromise the mucosal integrity and protective barrier 
function of the intestinal wall, leading to impaired gastrointestinal 
immune function and impaired resistance to pathogenic bacteria 
and antigens.79,81
Vagianos reported inadequate dietary intakes of vitamin A in 26% 
of patients with CD (n = 71). There was significantly lower median 
serum vitamin A in patients with active disease, compared to that in 
patients in remission.70 Serum carotene was low in more patients 
with CD with active disease compared to those with inactive disease, 
and was significantly lower in patients with small bowel involvement 
[66 patients (76%), p-value = 0.006]. Lower serum carotene levels 
were significantly associated with longer disease duration (> 20 
years). Routine multivitamin supplementation may be justified, 
regardless of disease type or activity. 
Magnesium and zinc deficiency
Deficiencies of magnesium (14-33%)36 and zinc (3-5%)82 are 
often a result of chronic diarrhoea, high-output stoma or fistulae, 
short bowel syndrome, bacterial overgrowth and malabsorption.36 
Zinc depletion causes phosphorylation-mediated disruption of the 
junction complexes and cytoskeletal disorganisation in Caco-2 cells, 
resulting in neutrophil migration.29 Zinc deficiency is associated with 
poor wound healing and fistulae formation, impaired membrane 
barrier function (both in vivo and in vitro), neutrophil migration and 
neutrophil accumulation in the intestinal lumen and epithelial crypts. 
This results in the formation of crypt abscesses.29,83 Supplementation 
aids to reduce intestinal permeability, and recommended dosages of 
8 mg elemental zinc twice a day, as zinc carnosine, for five days 
should be used when a deficiency is suspected.29
Exclusive enteral nutrition in active disease
Exclusive enteral nutrition (EEN) offers an alternative therapeutic 
approach with minimal side-effects, compared to corticosteroid 
or immunosuppressive therapy, when treating adults with CD.84 
In conjunction with improving overall nutrition status, growth and 
body composition, EEN has been shown to induce remission and 
mucosal healing, improve mucosal permeability, downregulate 
proinflammatory cytokines and reduce serum inflammatory 
markers.20,85-89 Primary nutrition therapy has been compared to 
steroid therapy in several studies, including three meta-analyses 
and two Cochrane systematic reviews.90-92 In terms of active 
disease, steroid treatment was more effective compared to EEN. 
There was no difference between elemental (free amino acids), 
semi-elemental (oligopeptides) and polymeric (whole protein- and 
glutamine-enriched) formulas to induce remission.93,94 For this 
reason, the European Crohn’s and Colitis Organisation54 (ECCO) 
recommends EEN only as a primary therapy for those who refuse 
drug therapy, and as an adjunct therapy in corticosteroid-refractory 
or corticosteroid-dependent disease in adults. In children, a meta-
analysis of 11 trials in 394 children with active CD demonstrated 
EEN to be equally effective as corticosteroid therapy [odds ratio 
(OR) 0.96, 95% confidence interval (CI): 0.6 to 1.14].95 The ECCO 
recommends that both EEN and corticosteroids are effective in 
inducing remission, regardless of disease location or activity.65
However, it should be noted that compliance with liquid diets is often 
problematic in adult patients. Withdrawal rates can reach 39%,92 
compared to low dropout and high compliance rates in children. 
Potentially, this explains the difference in efficacy. Issues that 
surround taste dislike (particularly elemental feeds), taste fatigue, 
boredom and poor support from, and contact with, dietetic staff, 
are common.96 Remission rates are as high as 80-85% in adult 
patients who do comply with a liquid diet.97,98 Interestingly, Japanese 
guidelines88 advocate nutrition therapy as first-line, and medication 
as second-line, therapy. This is important as corticosteroids often 
have limited efficacy in maintaining long-term remission and 
contribute to a range of side-effects, including osteoporosis.99-101
In a recent systematic review28 that examined the efficacy of EN in the 
maintenance of remission, significantly higher rates were reported 
in both surgically and medically induced remission patients when 
studies compared outcomes between patients who received EN and 
those who did not. In addition, significantly higher reoperation-free 
rates at five years were found in the EN supplemental group. In 
all seven studies, EN was provided immediately after induction of 
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remission, either as an oral or nocturnal nasogastric feed in addition 
to ordinary foods, and was never the sole source of nutrition. In five 
studies, an elemental EN diet that was administered via nocturnal 
nasogastric feeding was provided, in three of which patients were 
instructed to take 50% of energy from enteral feeds and 50% from 
low-fat food (20-30 g/day). Overall, this provided 35-40 kcal/kg 
IBW/day.28,102-108 The authors recommend that while polymeric feeds 
are often well tolerated orally during the day, nocturnal nasogastric 
tube feeds may be preferable when prescribing elemental formulas, 
because of poor palatability. Some international guidelines 
recommend polymeric feeds that are enriched with transforming 
growth factor-β2 (TGF-β2) as an alternative to elemental feeds.
109,110 
TGF-β2 is a protein that is secreted by the stomach and has been 
shown to exert anti-inflammatory properties. The protein reduces 
gastrointestinal inflammation, while its incorporation into polymeric 
feeds improves palatability and ultimately compliance.109,110
When offering liquid diets as a mode of therapy, whole-protein 
formulas may be advantageous in terms of cost, palatability and lower 
osmolarity.111,112 Practical considerations include the composition of 
available formulas, patient motivation and understanding of the diet, 
in addition to patient tolerance to formula and taste preferences. 
Elemental formulas may result in nausea and osmotic diarrhoea 
because of higher formula osmolarity, and these feeds must be 
introduced gradually over three to four days. Additional fluids should 
be provided to meet fluid requirements. In general, individuals 
who receive liquid diets may experience weight loss, hunger and 
diarrhoea, and volumes or concentrations should be adjusted 
accordingly.112
Formula composition
The amount of fat and the type of fatty acid that is present in 
formulas has been evaluated because of immunomodulatory and 
anti-inflammatory effects in the gut.20,113 Favourable outcomes have 
been associated with the low-fat (predominantly medium-chain 
triglyceride) content (0.6-1.3% of total calories),114 compared to 
the high-fat content (12-30% of total calories), particularly linoleic 
acid.113-115 However, a 2007 Cochrane systematic review94 examined 
the fat content variations in seven trials (n = 209) and found no 
significant difference between low-fat formulas (< 20 g/1 000 kcal) 
and high-fat formulas (> 20 g/1 000 kcal). Nevertheless, a trend, 
albeit nonsignificant, was noted that favoured very low-fat (< 3 g/ 
1 000 kcal) and low long-chain triglyceride content.
Omega-3 fatty acids decrease proinflammatory gene expression and 
cytokine production15 and have been shown to aid in the maintenance 
of remission in level-one studies. In a Cochrane systematic review 
and meta-analysis that examined six randomised control trials (RCTs) 
and two independent trials [Epanova Program in Crohn’s Study 1 
(EPIC-1) and Epanova Program in Crohn’s Study 1 (EPIC-2)],25 the 
pooled analysis of the six RCTs revealed statistically significant 
results [relative ratio (RR): 0.77, 95% CI: 0.61-0.98, p-value = 0.03 
and RR: 0.71, 95% CI: 0.54-0.93, p-value = 0.002) of n-3 and enteric-
coated n-3 supplementation, respectively. Conversely, findings from 
the two independent trials (EPIC-1 and EPIC-2) reported no clinical 
benefit. Despite the contradictory reports, when pooled together, 
marginally statistically significant results (RR: 0.77, 95% CI: 0.61-
0.98) were found. The authors concluded that while enteric-coated 
n-3 therapy was considered safe and well tolerated,116 existing data 
did not support routine supplementation to maintain remission in 
CD.25,65 A primary limitation to the presumed benefit was attributed 
to the clinical heterogeneity between the studies and a publication 
bias suggested by funnel plot analysis, wherein small negative 
trials were underrepresented.116 Moreover, based on the meticulous 
nature and large sample size of the EPIC trials (double that of the 
included six studies for pooled analysis), those results provided a 
more precise estimate of treatment efficacy and therefore could not 
recommend routine supplementation for remission maintenance. 
Further research is required to assess the effect of omega-3 fatty 
acids on proinflammatory cytokine production in CD.
Other nutritional agents, including glutamine, butyrate, curcumin 
(turmeric extract), ginsenosides (ginseng extract), lycopene and 
other flavonoids (generally found in fruits and vegetables) have 
been evaluated, based on potential anti-inflammatory, antioxidant, 
immunoregulatory and anabolic actions through interactions with 
gene expression.15,117-121
Total parenteral nutrition in active disease
In the past, bowel rest and the correction of nutritional deficiencies 
via total parenteral nutrition (TPN) was a recommended therapy 
in CD.122,123 TPN is an invasive treatment therapy that carries an 
increased risk of infection, while prolonged gut rest may result in 
reduced intestinal integrity and villi atrophy. A landmark randomised 
control trial of 51 patients with active CD by Greenberg et al 
allocated patients to one of three groups: TPN and nil by mouth 
(n = 17), a defined formula diet via nasogastric tube (n = 19), and 
peripheral parenteral nutrition (PPN) plus supplementary oral diet 
(n = 15).124 Remission occurred in 71% of patients on TPN, in 58% 
of patients receiving nasogastric feeds and in 60% of patients on 
PPN and the oral diet. After one year, of those who had achieved 
clinical remission, 42%, 55% and 56% maintained remission, 
respectively. The differences were not significant. While TPN is not 
a recommended therapy for inducing remission in patients with 
CD, the ECCO recommends the use of TPN for complex, fistulising 
disease and as a supplemental therapy when EN is contraindicated.54 
Starting with a continuous infusion and moving to cyclical delivery 
in stable or long-term patients may be preferable.125 Despite the 
potential complications,126 home TPN is a viable life-saving option 
for some patients and in select cases has proven to improve clinical 
outcome and eliminate the need for surgery.125,127
Diet to maintain remission
EN has shown a suppressive effect on disease activity and mucosal 
inflammatory cytokine levels, yet recommended duration of EN 
supplementation once remission is first achieved is unknown.108 A 
2009 Cochrane review84 of EN in the maintenance of remission in 
CD examined two randomised control trials. The first, a Japanese 
study, showed that outpatients who received half their daily caloric 
requirements as an elemental feed, and half as a normal diet, had 
a lower relapse rate (35%) compared to those who consumed a 
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full normal diet (64% relapse rate).128 The second UK-based study 
demonstrated no difference in the relapse rate, with regard to 
steroid therapy or surgery, of 33 adults when they were provided 
with 35-50% of nutrition requirements via a normal diet that was 
supplemented with either a whole-protein or semi-elemental sip 
feed.105 The study did not compare the two feeds to a normal diet 
alone. 
The review concluded that elemental or polymeric formulas might 
be used as an effective alternative, or as an adjunct treatment, 
to maintenance drug therapy during remission, yet optimal daily 
amounts are unknown. Interestingly, elimination diets have also been 
used to prolong remission after enteral feeding.129,130 These diets 
help patients to identify problem foods and create an individualised, 
“safe” diet plan. Limitations of elimination diets are that they are 
often complicated and require significant self-discipline and patient 
support. The diet is a lengthy process as reintroduction of foods may 
take up to three months and reactions to foods are often missed 
because of the slow onset of symptoms as new foods are tested 
several times over one day only. Alternatively, the low-fibre, fat-
limited, exclusion diet (LOFFLEX) offers a well-established option 
to the standard elimination diet and is as effective in maintaining 
remission compared to the standard elimination diet: 55.6% and 
59.4%, respectively.129 Patients are able to immediately reintroduce 
normally well-tolerated foods such as potato, rice, chicken or 
fish. while supplemented with nutritional sip feeds to ensure that 
nutritional adequacy for up to four weeks after remission is achieved 
initially. Thereafter, foods are individually introduced over four-day 
intervals until a complete normal diet is reached during a three- to 
four-week period. In light of the 2009 Cochrane review, in part, the 
success of the LOFFLEX diet may be because of prolonged use of 
EN in conjunction with a normal diet, in addition to the avoidance 
of poorly tolerated foods.96 This suggests that the protracted 
use of supplemental EN is beneficial once remission is achieved. 
Nevertheless, this modified elimination diet offers a more acceptable 
option for patients as a wider variety of foods is permitted, making 
mealtimes less restrictive and more socially acceptable. 
FODMAP
Up to 57% of patients with CD in long-standing remission report 
experiencing functional symptoms of abdominal pain, bloating, 
flatulence and diarrhoea, all of which impact on patients’ overall 
well-being and quality of life.131 Dietary restriction of fermentable 
oligosaccharides (fructans and galactans), disaccharides (lactose), 
monosaccarides (fructose) and polyols (FODMAP),132 may aid 
in reducing these functional symptoms (Table V). FODMAP are 
osmotically active short-chain carbohydrates that are poorly 
absorbed in the small intestine and rapidly fermented by bacteria 
in the colon. While ingestion does not cause the gastrointestinal 
disorder, it may lead to luminal distension, inducing the sensation 
of bloating, abdominal pain and often motility changes, particularly 
in individuals with existing bowel disease.132 As a low-FODMAP diet 
involves the avoidance of a wide range of foods, dietetic professional 
guidance is encouraged133-135 as patients tend to pick and choose 
aspects of the diet and ignore the rest, defeating the purpose, 
effectiveness and possibly nutritional completeness of the diet.132 
Patients require individual consultation and ongoing support, in 
addition to written literature, particularly when adapting the diet to 
locally available foods and prepackaged products.132,136 In order to 
identify the most problematic FODMAP foods, once eliminated, these 
foods are progressively introduced and tolerance is assessed, and, 
 Table IV: High-FODMAP food source and suitable food alternatives133
FODMAP food 
source
Fruits Vegetables Dairy Breads and cereals Sweeteners
High FODMAP Apples, apricots, cherries, lychees, 
peaches, pears, nashi pears, plums, 
prunes, mangoes, nectarines, sugar-
snap peas, watermelon, custard 
apples, white peaches, rambutans, 
persimmons and tinned fruit in 
natural juice
Concentrated fruit sources: Large 





fennel, garlic, leeks, 




Milk: Cow, goat and 
sheep, and ice cream
Yoghurt: Regular and 
low-fat
Cheeses: Soft and fresh, 
e.g. ricotta and cottage
Wheat and rye when 
eaten in large amounts, 
e.g. bread, pasta, 
couscous, crackers and 
biscuits
Fructose, high-fructose 
corn syrup, sorbitol, 
mannitol, xylitol, isomalt 






Bananas, blueberries, carambola, 
durian, grapefruit, grapes, 
honeydew melons, kiwi fruit, 
lemons, limes, mandarins, oranges, 
passion fruit, pawpaws, raspberries, 
rock melons, strawberries and 
tangelos
Bamboo shoots, bok 
choy, carrots, celery, 
capsicums, choko, choy 
sum, corn, eggplant, 
green beans, lettuce, 
chives, parsnip, 
pumpkin, silverbeet, 
spring onions (green 
only) and tomatoes
Onion and garlic 
substitutes: Garlic-
infused oil
Milk: Lactose-free and 
rice milk
Cheese: “Hard” cheeses, 
including Brie and 
Camembert
Yoghurt: Lactose-free
Ice cream substitutes: 
Gelati and sorbets
Butter
Gluten-free and spelt 




Maple syrup and golden 
syrup
FODMAP: fermentable oligosaccharides, disaccharides, monosaccarides and polyols
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in turn, the need to reduce or limit intake of specific FODMAP foods 
can then be identified.
Quercetin
Maintenance of epithelial barrier function and permeability is 
essential to prevent translocation by dietary antigens, microbes 
and other toxins.15 Impairment of epithelial permeability (mucosal 
integrity) allows for an increased antigen and bacterial uptake that 
potentially drives the inflammatory response and induces epithelial 
lesions.137-139 In CD, impaired mucosal integrity is common and 
characterised by alterations in the tight-junction protein content 
and composition, reductions in tight-junction strands and strand 
breaks.139 Interestingly, recent research now suggests that the 
dietary flavonoid, quercetin, may enhance barrier function and 
reduce intestinal permeability by “sealing” tight-junction protein, 
claudin-4, in the Caco-2 cells.139 The role of quercetin as a direct 
intestinal barrier-protective agent has been advocated.139 Food 
sources that are rich in quercetin include apples, capers, green tea, 
pears, cherries, grapes, red onions, kale, broccoli, leaf lettuce and 
garlic.
Probiotics
Probiotics may aid in maintaining CD remission by enhancing the 
immune and epithelial function of the gut.140 However, nonsignificant 
results from a meta-analysis, including eight randomised-control 
trials that examined probiotic efficacy for the maintenance of 
remission in CD,141 and a Cochrane systematic review142 that 
concluded that probiotic use cannot be recommended as effective 
therapy for the maintenance of remission in CD, do not indicate the 
use of probiotics in therapy currently. Treatment protocols, probiotic 
preparations, antibiotic use, disease behaviour and location, methods 
to induce remission and prior probiotic intestinal colonisation remain 
as limitations in previous study designs, potentially influencing 
probiotic efficacy.142
Summary
Nutritional support is considered to be an integral part of patient care 
in CD and should begin with individual patient assessment and take 
into consideration the potential limitations of standard anthropometric 
and biochemical indices. Unless contraindicated, EN should be 
used to aid in inducing remission. However, issues that surround 
patient tolerance and compliance may limit its implementation. After 
remission is achieved, the LOFFLEX and FODMAP diets can be used 
to transition and create individual patient diet plans. Throughout the 
disease course, preservation of bone stores and promotion of bone 
health is essential, including the assessment and supplementation of 
vitamins and minerals where clinically indicated.
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